IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced ...
As of December 31, 2024, Fortress' consolidated cash and cash equivalents totaled $57.3 million, compared to $58.9 million as ...
Pharmaceutical Technology on MSN4d
Macau approves IASO Bio’s multiple myeloma therapyThe Macau Special Administrative Region (ISAF) Pharmaceutical Administration Bureau has approved IASO Biotherapeutics’ new ...
This is the first NDA approval for Equecabtagene Autoleucel outside Mainland China. Equecabtagene Autoleucel (trade name: FUCASO) was approved by China's National Medical Products Administration ...
The Lok Sabha will take up the contentious Waqf (Amendment) Bill for discussion and passage today. NDA backed parties ...
Vanda Pharmaceuticals (VNDA) announced that a New Drug Application was submitted to the U.S. FDA requesting marketing approval of Bysanti for ...
Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from the FDA for its CARDAMYST NDA ...
Corcept's relacorilant hits phase 3 trial success in ovarian cancer, lifting shares 90%. Click here to find out why I rate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback